Table IV.

Progression free survival – reTURB vs. non-reTURB group comparison

Parameter	reTURB group			Non-reTURB group			Log-rank p	Cox HR* (95% CI) univariate
	1-year	2-year	5-year	1-year	2-year	5-year
All	91.0	89.4	80.2	88.4	81.5	70.6	0.031	1.58 (1.05–2.38)
Female	90.0	87.3	76.2	87.5	81.2	71.2	0.476	n.s.
Male	91.3	90.0	81.1	88.6	81.6	70.5	0.038	1.63 (1.03–2.57)
T1	89.7	87.9	78.6	91.9	87.2	74.8	0.617	n.s.
Ta	100	100	91.7	81.7	70.3	62.6	0.003	10.6 (1.43–77.82)
HG	90.7	88.9	78.2	83.7	75.8	63.3	0.004	1.92 (1.23–3.01)
LG	94.4	94.4	94.4	94.8	89.6	79.4	0.127	n.s.
TaHG	100	100	91.7	76.9	64.1	59.5	0.001	12.4 (1.65–93.67)
T1HG	89.2	87.2	76.2	86.7	80.9	65.2	0.114	n.s.
T1LG	94.4	94.4	94.4	97.6	94.0	84.3	0.252	n.s.
Muscle in primary TURB specimen: yes	91.4	89.3	80.0	89.1	83.9	70.8	0.092	n.s.
Muscle in primary TURB specimen: no	89.4	86.9	81.0	85.1	73.0	65.8	0.115	n.s.
T1 lamina propria focal infiltration	92.5	90.9	81.9	94.0	90.3	78.2	0.537	n.s.
T1 lamina propria massive infiltration	82.4	79.9	70.6	83.3	76.4	62.1	0.714	n.s.
Concomitant CIS: yes	88.2	88.2	80.0	84.9	69.5	57.6	0.123	n.s.
Concomitant CIS: no	92.1	89.7	80.5	89.3	84.7	73.9	0.149	n.s.
EORTC risk group: high	91.0	89.4	80.2	87.9	81.3	71.4	0.032	1.59 (1.04–2.44)
Focality: solitary	87.8	86.6	73.4	85.8	77.2	65.0	0.291	n.s.
Focality: multiple	93.3	91.2	84.6	90.0	83.6	75.2	0.061	n.s.
Primary	91.5	89.6	79.8	87.3	81.3	69.8	0.065	n.s.
Recurrent	88.9	88.9	82.5	89.2	81.7	71.2	0.260	n.s.
< 3 cm	89.2	88.4	75.8	92.6	85.8	72.5	0.388	n.s.
> 3 cm	93.8	91.0	85.0	83.2	75.2	67.8	0.013	2.45 (1.20–5.00)

TURB – transurethral resection of bladder tumour, CIS – carcinoma in situ, HR – hazard ratio, 95% CI – 95% confidence interval, the value of adjusted p < 0.05 was considered statistically significant (bolded); HR > 1 better outcome when reTURB performed, HR < 1 worse outcome when reTURB performed.